TABLE 1.

Survival of primary LVS infection by BALB/cByJ mice treated with anti-IL-12 antibodies

Treatmentai.d. dose of LVS (CFU)No. of deaths/total
PBS1040/5
1050/5
1066/29
Anti-IL-4 antibody1050/5
1067/16
Anti-IL-12 antibodies1042/10
1051/5
10620/29
  • a BALB/cByJ mice were treated i.p. with either 0.5 ml of PBS, 1 mg of anti-IL-4 antibody or a combination of 500μg of C15.G anti-IL-12 antibody plus 500 μg of C15.1 anti-IL-12 antibody on days −1, 0, 7, 14, and 21. On day 0, mice were infected i.d. with the indicated dose of LVS; actual doses were confirmed by plate count at the time of infection. Since deaths of normal mice from i.d. LVS infection occur between days 4 and 7, survival was monitored through at least day 11, at which time selected mice were sacrificed to assess bacterial burdens; most mice were monitored through day 24 before they were sacrificed. The combined results of five independent experiments, all with five or more mice per group, are shown.